www.fortunebusinessinsights.com/   joined
Fortune Business Insights™ | Global Market...

Read Full Biography
Shivv
@shivv Posted an update
3 years ago
Global Adalimumab Biosimilar Market to Expand with Rising Prevalence of Arthritis, Says Fortune Business Insights
Market Overview

The global “adalimumab biosimilar market” is poised to experience a steady growth period owing to the rising incidence of arthritis. According to the World Health Organization (WHO), rheumatoid arthritis affects 0.3 to 1% of people in the developed countries and about 50% of them are forced to quit their jobs after the onset of the disease. On the other hand, osteoarthritis hits 9.6% of men and 18% of women over the age of 60 globally. The Arthritis Foundation predicts that 78 million Americans will be suffering from arthritis by 2040, with 54 million already affected by it.

The global adalimumab biosimilar market stands to gain from this growing prevalence as adalimumab is an effective treatment option for various kinds of arthritis. A monoclonal antibody, adalimumab is designed to treat autoimmune diseases such as rheumatoid arthritis, Crohn’s Disease, ulcerative colitis, and many more. It achieves this by inhibiting the soluble inflammatory cykotine, Tumor Necrosis Factor (TNF). The product originated from AbbVie’s Humira, which got cleared by the US FDA in 2002 and the European Medicines Agency in 2003.
Dislike 0

Sitemap